Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation
Pain
Cataract

Interventions

DRUG: XG-102
DRUG: Placebo

Sponsor

Xigen SA